bullish

Aclaris Therapeutics Inc (ACRS) - Sunday, Mar 24, 2024

173 Views24 Jun 2024 08:06
Syndicated
SUMMARY
  • ACRC is a biotech pharma micro-cap company trading below its net cash value
  • Downsized workforce after a failed phase 2 trial, CEO and CMO left prompting strategic evaluation
  • Activist investors involved, potential for monetization of stakes to benefit shareholders.

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
chart-bar
Logo
Value Investors Club
External reports (aggregated public sources)
Value Investors Club
Equity Bottom-UpEvent-Driven
Price Chart(Sign Up to Access)
analytics-chart
  • Aclaris Therapeutics Inc (ACRS) - Sunday, Mar 24, 2024
    24 Jun 2024
x